Guanylate cyclase activity in normal and diseased human muscle

CESARE CERRI, NICOLA CANAL, AND LODOVICO FRATTOLA

From the Neurological Department, University of Milan, Milan, Italy

SUMMARY Guanylate cyclase activity has been studied in muscle of normal subjects and of patients suffering from muscular and neuromuscular diseases. In normal tissue a guanylate cyclase activity was found in both soluble and particulate fractions of homogenate. We found also that the kinetic analysis of the enzyme of soluble differed from that of particulate fraction. A decrease of guanylate cyclase activity in crude homogenate was observed in muscular dystrophies, in neuromuscular atrophies, and in inflammatory forms of muscle disease.

Although cyclic nucleotides are recognised as regulators of many physiological and pathological events, the mechanisms by which they act are still unclear.

In skeletal muscle cyclic nucleotides are involved in neurotrophic function, in synaptic transmission, in contraction, and in myogenesis (Goldberg et al., 1973; Takamori et al., 1973; Carlsen, 1975; Epstein et al., 1975; Kebabian et al., 1975; Stone et al., 1975; Standaert et al., 1976).

In human muscular pathological conditions, previous findings indicate that the activity of adenylate cyclase and of cyclic nucleotides phosphodiesterase are frequently altered (Canal and Frattola, 1974; Mawatari et al., 1974; Susheela et al., 1975; Canal et al., 1977).

Guanylate cyclase (EC.4.6.1.2), the enzyme that catalyses the conversion of guanosine triphosphate (GTP) to guanosine-3', 5'-monophosphate (cGMP), was present in particulate and soluble fractions of animal heart and skeletal muscle where it displayed different distribution and kinetic properties, and probably different physiological roles (Kimura and Murad, 1974; Sulahke et al., 1976).

In denervated skeletal muscle the activity of this enzyme is increased in all tissue fractions; in contrast, in the same muscle the adenylate cyclase activity is greatly decreased (Novom and Lewinstein, 1977). These observations, and the lack of information on guanylate cyclase studies in the human muscle, have led us to investigate this enzyme in the muscle of normal subjects and patients suffering from different muscular diseases.

Material and methods

HUMAN MATERIAL

Muscle samples were taken from deltoid or quadriceps muscles under local anaesthesia with 10 ml of procaine 2%, without adrenaline. Care was taken not to infiltrate the muscular tissue. The diagnosis was based on clinical criteria, electrophysiological, serological, and histochemical tests.

The group of neurogenic atrophies included spinal atrophies (juvenile forms), amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease; the group of muscular atrophy included the sex-linked forms (Duchenne's and Becker's forms). Control muscle samples were taken under local anaesthesia as the first procedure during orthopaedic operations from deltoid or quadriceps muscles of patients with no evidence of muscular disease.

All subjects had been kept without any pharmacological treatment for at least five days.

CHEMICAL MATERIAL

Guanosine 5'-triphosphate sodium salt (GTP), creatine phosphate sodium salt, creatine kinase (skeletal rabbit muscle), acetylcholine chloride (ACh), and Tris (tris-hydroxymethyl-aminomethane) were purchased from Boehringer GmbH. All
other reagents were of analytical grade. The radioimmunoassay kits were purchased from New England Nuclear Chemicals Gmbh.

**TISSUE PREPARATION**

All procedures for the enzyme preparation were carried out at 4°C. The tissue samples were homogenised in six volumes of 0.25 M sucrose containing 10 mmol Tris-HCl buffer pH 8.0 (at room temperature), using a Potter-Elvehjem homogeniser with Teflon pestle. The homogenate was centrifuged for 10 min at 1500 g (av) to remove debris, and the supernatant thus obtained was employed as crude homogenate preparation. Aliquots of this homogenate preparation were centrifuged at 40000 g (av) for 90 min. While the supernatant was used as soluble (or supernatant) fraction, the resulting pellets were suspended in a volume of homogenising buffer equal to that of the original homogenate and used as the particulate fraction. Because of the small tissue samples, in pathological conditions the subcellular distribution of the enzyme was not studied, and in pathological tissues the guanylate cyclase activity was investigated only in crude homogenates.

**ASSAY OF GUANYLATE CYCLASE**

The method of Kimura et al. (1975) was used to determine guanylate cyclase activity. The standard incubation mixture, in a final volume of 100 μl, contained 50 mmol/l Tris-HCl buffer (pH 7.6 at 37°C), 10 mmol/l theophylline, 2 mmol/l MnCl₂, 15 mmol/l creatine phosphate, 20 μg of creatine kinase and 40 μl of enzyme preparation.

Guanylate cyclase activity was started by adding 2 mmol/l GTP to the reaction mixture (preincubated for 10 min at 37°C), and it was run at 37°C for 15 min. To prevent nonenzymatic formation of cGMP the reaction was stopped by adding 0.9 ml of 50 mmol/l sodium acetate buffer (pH 4.0) and then heated for 3 min at 90°C. Samples incubated with boiled enzymes were used as controls.

Reactions were performed in triplicate. The heated incubation extracts were centrifuged at 1500 g for 15 min and aliquots of 100 μl were assayed for cGMP using the radioimmunoassay of Steiner et al. (1972). Noncollagenous protein concentration was determined according to the method of Lowry et al. (1951) after alkal digestion by the procedure of Lillienthal et al. (1950).

The kinetic analysis was carried out only in the soluble and particulate fractions. Enzyme activity data were plotted in the presence of various concentrations of substrate according to the procedure of Lineweaver and Burk (1934).

In comparison between normal and pathological groups, the statistical significance of the results was determined by Student's two-tailed t test.

**Results**

Results of the kinetic analysis for guanylate cyclase in normal skeletal muscle are shown in the Figure. For the soluble fraction the apparent Kₘ of the enzyme is about 132 μM, while the Michaelis constant for the particulate fraction is about 31 μM.

The Figure shows that some difference can also be observed in the Vmax of the enzyme present in the two subcellular preparations, that of the soluble being slightly higher than that of the particulate fraction.

Table 1 shows the data on enzyme measurement in the homogenate, in the soluble and in particulate fractions of normal skeletal muscle. In the homogenate the cGMP formed by 1 mg of protein in 15 min was 82.5±6.3 pmol, in the soluble and particulate it was 39.4±10.2 pmol and 161.4±55.1 pmol respectively.

In normal subjects no difference in guanylate cyclase activity was observed as far as age, sex, and muscle used (deltoid or quadriceps) were concerned.

![Figure](http://jnnp.bmj.com/) Double reciprocal plot of cGMP formation as a function of cGMP concentration in a soluble (●) and particulate (○) fraction of normal human skeletal muscle. The conditions of the assay are described in Material and Methods section. Each point represents the mean of four determinations.
In our experimental conditions the cGMP formed was linear with respect to protein concentration (up to 200 μg) and incubation time (up to 30 min).

We have measured guanylate cyclase activity in presence of different concentrations of Mn++ (0.5, 1, 2, 3, and 4 mmol/l). The maximal response was observed in the presence of 2 mmol/l MnCl₂. No further increased activity was observed with 3 mmol/l of MnCl₂, while at 4 mmol/l the activity was slightly decreased. The influence of Mn++ in activating the enzyme was similar for soluble and particulate fraction.

Cholinergic agents are not able to stimulate the guanylate cyclase. In fact, Table 1 shows that the addition of 25 μmol/l ACh to the incubation mixture does not increase the cGMP formation.

As indicated in Table 2, in comparison with normal tissue, we found a significant decrease of enzyme activity in the homogenate of muscular dystrophies, neurogenic atrophies, and polymyositis, while in myotonic dystrophy and in myasthenia gravis the level of guanylate cyclase is in the normal range.

The results obtained in the muscle of patients suffering from mitochondrial myopathy are of particular interest: although only two cases were studied, both showed a remarkably low enzymatic activity.

### Table 1 Guanylate cyclase activity in normal skeletal muscle

<table>
<thead>
<tr>
<th>Reaction mixture</th>
<th>Crude homogenate</th>
<th>Supernatant</th>
<th>Particulate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Without additions (10)</td>
<td>82.5 ± 6.3</td>
<td>39.2 ± 10.2</td>
<td>161.4 ± 55.2</td>
</tr>
<tr>
<td>With 25 μmol/l ACh (5)</td>
<td>89.1 ± 5.8</td>
<td>43.4 ± 11.2</td>
<td>152.3 ± 56.1</td>
</tr>
</tbody>
</table>

Data represent the mean ± SD; values expressed as pmol of cGMP formed/15 minutes/milligram of noncollagenous protein; number of subjects in brackets.

### Discussion

The results of the present study demonstrate the presence of a guanylate cyclase activity in human skeletal muscle. The enzyme is present in both soluble and particulate fraction of the homogenate, where it shows different distribution and kinetic properties. In normal tissue the enzymatic activity of the particulate fraction is higher than that of the soluble, while the Kₘ is lower in particulate than in soluble fraction.

Our findings that optimal activity of enzyme require the presence of low concentration of Mn++ (2 mmol/l in our experimental conditions), are in agreement with those observed in the heart or skeletal muscle of animals (Kimura and Murad, 1974; Sulahke et al., 1977).

Several reports suggest that cholinergic agents also stimulate the guanylate cyclase in broken cell preparations (Goldberg et al., 1973; De Rubertis and Craven, 1976). In our study the addition of acetylcholine to the incubation mixture did not increase the cGMP formation. The same conclusion has been published recently by Novom and Lewinstein (1977) in subcellular preparations of normal and denervated skeletal muscle of rabbits.

In the homogenate of some muscular diseases the regulation of guanylate cyclase system seems to be altered (Table 2). In particular we found a significant and similar decrease of enzyme activity both in myopathies and in neurogenic atrophies of muscle. These data could lead to the conclusion that in human muscular atrophies the change in guanylate cyclase activity is not related to the neurogenic or myogenic origin of the amyotrophy. On the other hand, it should be emphasised that the change of guanylate cyclase in human chronic neurogenic atrophies is in the opposite direction to that observed by Novom and Lewinstein (1977) in the skeletal muscle of rabbits after denervation, where the enzyme activity is “increased several times.”

As the metabolic role and physiological significance of cGMP in skeletal muscle is not yet known, it is difficult to explain its alterations in pathological conditions. In an attempt to clarify the mechanisms for regulation of guanylate cyclase system in human skeletal muscle, we are carrying out a study of the subcellular distribution, kinetic properties, and pharmacological responsiveness of this enzyme in patients suffering from muscular or neuromuscular diseases. Our preliminary data regarding two cases of Duchenne's dystrophy indicate that guanylate cyclase activity is present mostly in the soluble fraction of the homogenate, while in neurogenic atrophies—one
case of amyotrophic lateral sclerosis and two
cases of spinal atrophies—the enzyme does not
show significant changes in subcellular distribution.

We appreciate Miss Andreina Bordoni’s helpful
suggestions during the experiments.

References

and adenylylcyclase in normal and diseased muscle.
In Recent Advances in Myology, pp. 273–276. Edited
by W. G. Bradley, D. Gardner-Medwin, and J. N.

Canal, N., Cerri, C., Musch, B., and Frattola, L.
(1977). Metabolism of cyclic nucleotides in healthy
and diseased human muscle. Israel Journal
of Medical Sciences, 13, 147–151.

Carlsen, R. C. (1975). The possible role of cyclic AMP
in the neurotrophic control of skeletal muscle.

erties of the guanylate cyclase-guanosine 3′–5′
monophosphate system in rat adrenal cortex. Journal
of Biological Chemistry, 251, 4651–4658.

Epstein, C. J., Jimenez, de Asua, L., and Rozengurt,
Journal of Cellular Physiology, 86, 83–90.

Goldberg, N. D., O’Dea, N. F., and Hadden, M. R.
(1973). Cyclic AMP. In Advances in Cyclic
York.

Kebabian, J. W., Steiner, A. L., and Greengard, P.
(1975). Muscarinic cholinergic regulation of cGMP
in autonomic ganglia: possible role in synaptic
transmission. Journal of Pharmacology and Exper-
imental Therapeutics, 193, 474–488.

Activation of guanylate cyclase from rat liver and
other tissue by sodium azide. Journal of Biological
Chemistry, 250, 8016–8022.

different forms of guanylate cyclase in rat heart.
Journal of Biological Chemistry, 249, 6910–6916.

Cesare Cerri, Nicola Canal, and Lodovico Frattola

Lillienthal, J. L., Lierlor, K. L., and Folk, B. P.
(1950). A reference base and system for analysis of
muscle constituents. Journal of Biological Chemistry,
185, 501–509.

Lineweaver, H., and Burk, D. (1934). The determi-
ation of enzyme dissociation constants. Journal of
American Chemical Society, 56, 658–665.

Lowry, O. H., Rosebrough, N. J., Farr, A. L., and
Randall, R. J. (1951). Protein measurement with the folin phenol reagent. Journal of Biological
Chemistry, 193, 265–275.

Adenyl cyclase in normal and pathological human
muscle. Archives of Neurology (Chicago), 30, 96–
102.

cyclase and guanylate cyclase of normal and denervated skeletal muscle. Neurology (Minneapolis),
27, 869–874.

Standaert, F. G., Dretchen, K. L., Skirboll, L. R.,
and Morgenroth, V. H. (1976). A role of cyclic nucleo-
tides in neuromuscular transmission. Journal of
Pharmacology and Experimental Therapeutics, 199,
553–564.

Radioimmunoassay for cyclic nucleotides. Journal
of Biological Chemistry, 247, 1106–1113.

Cyclic AMP and cyclic GMP may mediate opposite
neuronal responses in the rat cerebral cortex.

Sulahke, S. J., Leung, N. L., and Sulahke, P. V.
(1977). Interactions of divalent cations and nucleo-
tides with solubilised cardiac guanylate cyclase.
Enzyme, 22, 141–144.

Sulahke, P. V., Sulahke, S. J., Leung, N. L., St. Louis,
subcellular distribution in cardiac muscle, skeletal
muscle, cerebral cortex and liver. Biochemical

Susheela, A. K., Kaul, R. D., Sachdiva, K., and Singh,
N. (1975). Adenylate cyclase activity in Duchenne
dystrophic muscle. Journal of the Neurological
Sciences, 24, 361–363.

of cyclic AMP in neuromuscular transmission.
Archives of Neurology (Chicago), 29, 420–424.